New challenges for HDL-modifying therapies as a strategy to lower cardiovascular disease events in statin-treated patients

Cardiovasc Drugs Ther. 2015 Feb;29(1):1-3. doi: 10.1007/s10557-015-6576-7.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • ATP Binding Cassette Transporter 1 / metabolism*
  • Animals
  • Cholesterol / metabolism*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Lipoproteins, HDL / metabolism*
  • MicroRNAs / metabolism*
  • Simvastatin / pharmacology*

Substances

  • ATP Binding Cassette Transporter 1
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins, HDL
  • MicroRNAs
  • Cholesterol
  • Simvastatin